SRC and leukemia: The HEM-iSMART sub-protocol B phase I/II trial (NCT05751044) will evaluate the safety and efficacy of dasatinib in combination with venetoclax + dexamethasone + cyclophosphamide and cytarabine in children and AYAs with R/R B- and T-ALL, whose leukemia presents with alterations in the MAPK/SRC pathway.